Trulieve Successfully Lists on NYSE, Marking Industry Milestone
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Source: NASDAQ.COM
- Industry Milestone: Trulieve Cannabis has successfully listed on the New York Stock Exchange, becoming the first U.S.-based marijuana company to trade on a major exchange, significantly broadening its investor base and enhancing market visibility.
- Strong Financial Performance: The company generated approximately $1.2 billion in revenue and reported an operating profit of $149 million over the past 12 months, demonstrating its robust competitiveness and financial health in the rapidly growing marijuana market.
- Market Potential: According to estimates from Grand View Research, the U.S. marijuana market is projected to reach $76 billion by 2030, with a compound annual growth rate of 11.5%, providing Trulieve with substantial growth opportunities, particularly in the medical and recreational marijuana sectors.
- Investment Appeal: Despite a market cap of less than $2 billion, Trulieve stands out as an attractive option for growth-oriented investors due to its 170 dispensaries in Florida and strong market position, especially as marijuana legalization continues to advance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TRLV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TRLV
Wall Street analysts forecast TRLV stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 9.450
Low
Averages
High
Current: 9.450
Low
Averages
High
No data
About TRLV
Trulieve Cannabis Corp. is a vertically integrated cannabis company. The Company has established cannabis operations in three hubs: Southeast, Northeast, and Southwest. Each of its three regional hubs is anchored by market positions in the cornerstone states of Florida, Pennsylvania, and Arizona. The Company operates in regulated markets that require expertise in cultivation, manufacturing, and retail. The Company utilizes various extraction techniques, including supercritical ethanol extraction, carbon dioxide extraction, hydrocarbon extraction, and mechanical separation. In addition, it utilizes distillation, purification, and manufacturing technologies to further refine extracts and transform them into a wide variety of finished products. Its brands include premium-tier brands Avenue, Cultivar Collection, and Muse; mid-tier brands Modern Flower, Alchemy, Momenta, and Sweet Talk, and value tier brands Co2lors, Loveli, Roll One, and Trekkers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Recommendations for Cava, Immunitybio, and Trulieve
- Cava's Investment Outlook: Cava is highlighted as the most promising stock among new concepts, with Jim Cramer noting its tasty, healthy, and fun attributes that appeal to a broad consumer base, likely driving its stock price higher.
- Speculative Opportunity in Immunitybio: Cramer recommends Immunitybio as a sole speculative investment, emphasizing the strategy of focusing on a single position in the market, which could yield high returns for investors.
- Unique Value of Trulieve: Cramer identifies Trulieve as the standout stock, asserting its significant investment value and encouraging investors to pay attention to its future performance, which may attract more investor interest.
- Hold Recommendation for Ashland: Cramer believes Ashland's current stock price is undervalued, advising investors to hold onto the stock as he anticipates a price increase that reflects its potential market value.
See More
Trulieve's NYSE Listing Marks Milestone for Marijuana Industry
- Industry Milestone: Trulieve Cannabis's listing on the NYSE as the first U.S.-based marijuana company to trade on a major exchange signifies a major advancement for the industry, likely attracting increased investor interest in the sector.
- Strong Financial Performance: The company generated approximately $1.2 billion in revenue and reported an operating profit of $149 million over the past 12 months, demonstrating robust growth potential in the medical marijuana sector and solidifying its market leadership.
- Market Opportunities: With projections indicating that the U.S. marijuana market could reach $76 billion by 2030, averaging an 11.5% annual growth rate, Trulieve is well-positioned to capitalize on significant expansion opportunities in both medical and recreational marijuana markets.
- Investment Appeal: Despite a market cap of less than $2 billion, Trulieve's stock has risen 12% this year, and its strong financials and dominant market position make it an attractive option for long-term investors, particularly those willing to embrace the risks associated with marijuana stocks.
See More
Trulieve Successfully Lists on NYSE, Marking Industry Milestone
- Industry Milestone: Trulieve Cannabis has successfully listed on the New York Stock Exchange, becoming the first U.S.-based marijuana company to trade on a major exchange, significantly broadening its investor base and enhancing market visibility.
- Strong Financial Performance: The company generated approximately $1.2 billion in revenue and reported an operating profit of $149 million over the past 12 months, demonstrating its robust competitiveness and financial health in the rapidly growing marijuana market.
- Market Potential: According to estimates from Grand View Research, the U.S. marijuana market is projected to reach $76 billion by 2030, with a compound annual growth rate of 11.5%, providing Trulieve with substantial growth opportunities, particularly in the medical and recreational marijuana sectors.
- Investment Appeal: Despite a market cap of less than $2 billion, Trulieve stands out as an attractive option for growth-oriented investors due to its 170 dispensaries in Florida and strong market position, especially as marijuana legalization continues to advance.
See More
Tilray Brands Faces Increased Competition Amid Market Changes
- Stock Decline: Tilray Brands' stock has plummeted 45% in 2026, indicating ongoing challenges in a competitive market, particularly after the legalization of cannabis in Canada led to increased competition and regulatory hurdles.
- Strategic Shift: In response to market pressures, Tilray has pivoted towards beverages and acquired craft brewers in an attempt to diversify its business and boost sales, yet this strategy has not significantly improved its financial performance.
- Increased Competition: The recent NYSE listing of Trulieve Cannabis allows investors easier access to the U.S. marijuana market, potentially diminishing interest in Tilray's stock and exacerbating its loss of market share.
- Financial Struggles: Tilray has reported operating losses for the past four quarters and has struggled to achieve consistent growth, leading to diminished investor confidence in its value, despite its seemingly low valuation.
See More
Tilray Faces Competitive Pressures and Market Challenges
- Increased Market Competition: Trulieve's recent uplisting on the New York Stock Exchange may attract investor attention, weakening Tilray's market position and contributing to a 45% decline in its stock price so far in 2026.
- Poor Financial Performance: Tilray has incurred operating losses in each of the past four quarters and has struggled to achieve consistent growth, highlighting its vulnerability in a competitive market environment.
- Limited Strategic Transformation: While Tilray attempts to diversify its business through craft brewer acquisitions and international market expansion, the lack of direct exposure to the U.S. market limits its growth potential, leading investors to prefer Trulieve.
- Decreased Investment Appeal: Given Tilray's weak fundamentals and uncertain future, analysts advise caution for potential investors, especially since Tilray was not included in the Motley Fool's list of 10 best stocks to buy.
See More
Trulieve Successfully Lists on NYSE, Opening Doors for Cannabis Sector
- Industry First Listing: Trulieve Cannabis has become the first U.S. cannabis operator to list on the New York Stock Exchange under the ticker “TRLV,” marking a significant step towards financial normalization in the cannabis sector and potentially attracting more institutional capital.
- Successful Structural Adjustment: To meet listing requirements, Trulieve restructured its business to ensure that the listed entity consists entirely of medical marijuana operations while retaining revenue from the recreational cannabis market, providing economic exposure to the broader cannabis market.
- Improved Market Access: With Trulieve's listing, institutional investors, pension funds, and mutual funds will find it easier to enter this market, which is expected to increase trading volume and liquidity, enhancing market efficiency, although this does not guarantee stock price increases.
- Risks Remain: Despite the new opportunities presented by the listing, the cannabis industry still faces challenges such as high debt, market saturation, and regulatory uncertainty, which could impact the long-term profitability and market performance of companies in this sector.
See More
Investment Recommendations for Cava, Immunitybio, and Trulieve
- Cava's Investment Outlook: Cava is highlighted as the most promising stock among new concepts, with Jim Cramer noting its tasty, healthy, and fun attributes that appeal to a broad consumer base, likely driving its stock price higher.
- Speculative Opportunity in Immunitybio: Cramer recommends Immunitybio as a sole speculative investment, emphasizing the strategy of focusing on a single position in the market, which could yield high returns for investors.
- Unique Value of Trulieve: Cramer identifies Trulieve as the standout stock, asserting its significant investment value and encouraging investors to pay attention to its future performance, which may attract more investor interest.
- Hold Recommendation for Ashland: Cramer believes Ashland's current stock price is undervalued, advising investors to hold onto the stock as he anticipates a price increase that reflects its potential market value.
See More
Trulieve's NYSE Listing Marks Milestone for Marijuana Industry
- Industry Milestone: Trulieve Cannabis's listing on the NYSE as the first U.S.-based marijuana company to trade on a major exchange signifies a major advancement for the industry, likely attracting increased investor interest in the sector.
- Strong Financial Performance: The company generated approximately $1.2 billion in revenue and reported an operating profit of $149 million over the past 12 months, demonstrating robust growth potential in the medical marijuana sector and solidifying its market leadership.
- Market Opportunities: With projections indicating that the U.S. marijuana market could reach $76 billion by 2030, averaging an 11.5% annual growth rate, Trulieve is well-positioned to capitalize on significant expansion opportunities in both medical and recreational marijuana markets.
- Investment Appeal: Despite a market cap of less than $2 billion, Trulieve's stock has risen 12% this year, and its strong financials and dominant market position make it an attractive option for long-term investors, particularly those willing to embrace the risks associated with marijuana stocks.
See More
Trulieve Successfully Lists on NYSE, Marking Industry Milestone
- Industry Milestone: Trulieve Cannabis has successfully listed on the New York Stock Exchange, becoming the first U.S.-based marijuana company to trade on a major exchange, significantly broadening its investor base and enhancing market visibility.
- Strong Financial Performance: The company generated approximately $1.2 billion in revenue and reported an operating profit of $149 million over the past 12 months, demonstrating its robust competitiveness and financial health in the rapidly growing marijuana market.
- Market Potential: According to estimates from Grand View Research, the U.S. marijuana market is projected to reach $76 billion by 2030, with a compound annual growth rate of 11.5%, providing Trulieve with substantial growth opportunities, particularly in the medical and recreational marijuana sectors.
- Investment Appeal: Despite a market cap of less than $2 billion, Trulieve stands out as an attractive option for growth-oriented investors due to its 170 dispensaries in Florida and strong market position, especially as marijuana legalization continues to advance.
See More
Tilray Brands Faces Increased Competition Amid Market Changes
- Stock Decline: Tilray Brands' stock has plummeted 45% in 2026, indicating ongoing challenges in a competitive market, particularly after the legalization of cannabis in Canada led to increased competition and regulatory hurdles.
- Strategic Shift: In response to market pressures, Tilray has pivoted towards beverages and acquired craft brewers in an attempt to diversify its business and boost sales, yet this strategy has not significantly improved its financial performance.
- Increased Competition: The recent NYSE listing of Trulieve Cannabis allows investors easier access to the U.S. marijuana market, potentially diminishing interest in Tilray's stock and exacerbating its loss of market share.
- Financial Struggles: Tilray has reported operating losses for the past four quarters and has struggled to achieve consistent growth, leading to diminished investor confidence in its value, despite its seemingly low valuation.
See More
Tilray Faces Competitive Pressures and Market Challenges
- Increased Market Competition: Trulieve's recent uplisting on the New York Stock Exchange may attract investor attention, weakening Tilray's market position and contributing to a 45% decline in its stock price so far in 2026.
- Poor Financial Performance: Tilray has incurred operating losses in each of the past four quarters and has struggled to achieve consistent growth, highlighting its vulnerability in a competitive market environment.
- Limited Strategic Transformation: While Tilray attempts to diversify its business through craft brewer acquisitions and international market expansion, the lack of direct exposure to the U.S. market limits its growth potential, leading investors to prefer Trulieve.
- Decreased Investment Appeal: Given Tilray's weak fundamentals and uncertain future, analysts advise caution for potential investors, especially since Tilray was not included in the Motley Fool's list of 10 best stocks to buy.
See More
Trulieve Successfully Lists on NYSE, Opening Doors for Cannabis Sector
- Industry First Listing: Trulieve Cannabis has become the first U.S. cannabis operator to list on the New York Stock Exchange under the ticker “TRLV,” marking a significant step towards financial normalization in the cannabis sector and potentially attracting more institutional capital.
- Successful Structural Adjustment: To meet listing requirements, Trulieve restructured its business to ensure that the listed entity consists entirely of medical marijuana operations while retaining revenue from the recreational cannabis market, providing economic exposure to the broader cannabis market.
- Improved Market Access: With Trulieve's listing, institutional investors, pension funds, and mutual funds will find it easier to enter this market, which is expected to increase trading volume and liquidity, enhancing market efficiency, although this does not guarantee stock price increases.
- Risks Remain: Despite the new opportunities presented by the listing, the cannabis industry still faces challenges such as high debt, market saturation, and regulatory uncertainty, which could impact the long-term profitability and market performance of companies in this sector.
See More
